Assignee
JIANGSU HENGRUI PHARMACEUTICALS CO LTD
CN·4 granted patents·76 pending applications·4 citations·filing 2021–2025
Top patents by PatentIndex Score
80 records- 0194US12227499B2Fused imidazole derivative, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Granted Feb 18, 2025·4 cites·18 claims
- 0285US12473279B2Fused imidazole derivative, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2024·Granted Nov 18, 2025·0 cites·6 claims
- 0378US12459937B2Fused imidazole derivative, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2025·Granted Nov 4, 2025·0 cites·20 claims
- 0471US2025282773A1Fused imidazole derivative, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2025·Application pending·0 cites
- 0565US2026055088A1Heterocyclic compound, method for preparing same, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 0664US2025376519A1Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 0762US2025057968A1Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibodyJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0861US2025043022A1Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 0961US2026056186A1Method for screening and preparing immunomodulatorJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 1060US2025197390A1Fused heterocyclic compound, and preparation method therefor and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 1160US2024352113A1Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its applicationJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1260US2026028421A1Antigen-binding molecule specifically binding to gucy2c and cd3 and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 1360US2024270874A1Anti-klb antibodies and usesJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1460US2024352132A1Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1560US2024400670A1Anti-il23 antibody fusion protein and uses thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1660US2025382287A1Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing sameJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 1759US2025122211A1Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1859US2025026842A1Modified protein or polypeptideJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 1959US2025145637A1Sulfonamide derivative, preparation method therefor and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2059US2025129074A1Chimeric compound for targeted degradation of androgen receptor protein, preparation method therefor, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2158US2024301031A1Truncated taci polypeptide and fusion protein and use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2258US2025206760A1Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 2358US2024327388A1Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticalsJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2458US2024392020A1Antigen-binding moleculeJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2557US2025326743A1Crystal forms of triazine dione derivative and preparation method thereforJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 2657US2025121081A1Anti-ror1 antibody, and anti-ror1 antibody-drug conjugate and medical uses thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2757US2025320194A1Pharmaceutically acceptable salt and crystal form of fused pyridine ring derivative and preparation method thereforJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2857US2026014232A1Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use ThereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 2957US2026098027A1Pharmaceutically acceptable salt and crystal form of tetrahydronaphthalene derivative, and preparation methodJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 3056US2025340661A1Anti cd40 antibody, antigen binding fragment and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 3156US2024024498A1Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical compositionJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3256US2024016931A1Anti-tslp antibody pharmaceutical composition and use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3356US2024026028A1Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3456US2023416352A1Pharmaceutical composition comprising anti-connective tissue growth factor antibodyJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3556US2025099596A1Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicineJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 3655US2025144077A1Dosage regimen for thrombopoietin receptor agonistJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 3755US2024254245A1Antigen binding molecule specifically binding to rankl and ngf, and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 3855US2024360133A1Fused tricyclic compound, preparation method therefor and application thereof in medicineJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 3955US2024327434A1Fused tetracyclic compound, preparation method therefor and application thereof in medicineJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 4055US2025064750A1Lipid and composition used for deliveryJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 4154US12590081B2Fused imidazole derivatives, preparation method and medicinal use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Granted Mar 31, 2026·0 cites·21 claims
- 4254US2025145641A1Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method thereforJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 4354US2025154126A1Crystalline form of sulfur-containing isoindoline derivativeJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 4454US2025000989A1Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 4554US2025215083A1Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2023·Application pending·0 cites
- 4654US2024269307A1Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 4754US2024376204A1Protein specifically binding to pd-1 and pharmaceutical use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 4854US2025049777A1Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method thereforJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 4954US2024010639A1Triazine dione derivative, preparation method therefor and application thereof in medicineJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 5053US2025051467A1Fap/cd40 binding molecule and medicinal use thereofJIANGSU HENGRUI PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
Showing the top 50 of 80 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when JIANGSU HENGRUI PHARMACEUTICALS CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →